PACIRA BIOSCIENCES, INC.

(PCRX)
  Rapport
Geschatte realtime Cboe BZX  -  21:35 17-08-2022
57.98 USD   +0.05%
04/08PACIRA BIOSCIENCES, INC. : RBC Capital Markets ontvangt een koopadvies
MM
03/08Pacira BioSciences Q2 Non-GAAP EPS daalt, inkomsten stijgen
MT
03/08Winstflits (PCRX) PACIRA BIOSCIENCES boekt Q2 inkomsten $169,4M
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société PACIRA BIOSCIENCES, INC.
10/08PACIRA BIOSCIENCES : Reports Preliminary Net Product Sales of $50.2 Million for July 2022 ..
PU
10/08Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
GL
09/08NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communiti..
GL
09/08NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communiti..
GL
03/08PACIRA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
03/08PACIRA BIOSCIENCES : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
03/08PACIRA : Q2 Earnings Snapshot
AQ
03/08Pacira BioSciences Reports Second Quarter 2022 Financial Results
GL
03/08Pacira BioSciences Reports Second Quarter 2022 Financial Results
AQ
02/08Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthca..
GL
02/08Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthca..
AQ
27/07Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
GL
27/07Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
GL
14/07PACIRA BIOSCIENCES : Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million - F..
PU
14/07Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million
GL
16/06National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Prog..
GL
16/06National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Prog..
PR
14/06PACIRA BIOSCIENCES : Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46...
PU
14/06Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46..
GL
14/06Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46..
AQ
10/06PACIRA BIOSCIENCES, INC. : Change in Directors or Principal Officers, Submission of Matter..
AQ
02/06Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conferen..
GL
25/05Pacira BioSciences and the National Senior Games Association Break a GUINNESS WORLD REC..
PR
12/05Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45..
GL
10/05Pacira BioSciences to Present at Two Healthcare Conferences in May
GL
10/05Pacira BioSciences to Present at Two Healthcare Conferences in May
AQ
04/05PACIRA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
04/05PACIRA : Q1 Earnings Snapshot
AQ
04/05PACIRA BIOSCIENCES, INC. : Results of Operations and Financial Condition, Change in Direct..
AQ
04/05Pacira BioSciences Reports First Quarter 2022 Financial Results
GL
04/05Pacira BioSciences Reports First Quarter 2022 Financial Results
AQ
27/04Pacira to Report First Quarter 2022 Financial Results on Wednesday May 4, 2022
GL
12/04PACIRA BIOSCIENCES : Reports Preliminary Revenues of $157.4 to $158.4 Million for the Firs..
PU
12/04Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the Fir..
AQ
05/04Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual H..
AQ
15/03PACIRA BIOSCIENCES : Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42...
PU
15/03Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $4..
AQ
09/03Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Co..
AQ
28/02PACIRA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
24/02PACIRA : Q4 Earnings Snapshot
AQ
24/02PACIRA BIOSCIENCES : Reports Full-Year and Fourth Quarter 2021 Financial Results - Form 8-..
PU
24/02Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
AQ
16/02Pacira to Report 2021 Financial Results on Thursday February 24, 2022
AQ
15/02PACIRA BIOSCIENCES : Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37...
PU
15/02Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37..
GL
07/02PACIRA BIOSCIENCES, INC. Financial Statements and Exhibits (form 8-K/A)
AQ
07/02PACIRA BIOSCIENCES : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS - Form 8-..
PU
06/01PACIRA BIOSCIENCES : Reports Preliminary Unaudited Total Revenue for 2021 of of $540.7 Mil..
PU
06/01Pacira Reports Preliminary Unaudited Total Revenue for 2021 of $540.7 Million to $541.7..
AQ
03/01Pacira BioSciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021PACIRA BIOSCIENCES : Announces Closing of $375 Million Five-Year Term Loan B - Form 8-K
PU
2021PACIRA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
2021Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B
GL
2021PACIRA BIOSCIENCES : Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48..
PU
2021Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $4..
AQ
2021Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confe..
GL
2021PACIRA BIOSCIENCES : Completes Acquisition of Flexion Therapeutics and Strengthens Leaders..
PU
2021PACIRA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
2021Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leader..
GL
2021Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leader..
GL
2021Pacira BioSciences to Present at the Jefferies London Healthcare Conference
GL
2021Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2..
PU
2021Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2..
GL
2021Pacira Files Lawsuit Against eVenus for Patent Infringement
AQ
2021PACIRA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
2021Pacira BioSciences Reports Third Quarter 2021 Financial Results - Form 8-K
PU
2021PACIRA : Q3 Earnings Snapshot
AQ
2021Pacira BioSciences Reports Third Quarter 2021 Financial Results
AQ
2021Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition
GL
2021Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021
GL
2021PACIRA BIOSCIENCES : to Acquire Flexion Therapeutics Further Expanding Leadership Position..
PU
2021PACIRA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Results of Operatio..
AQ
2021PACIRA BIOSCIENCES : to Acquire Flexion Therapeutics Further Expanding Leadership Position..
GL
2021PACIRA BIOSCIENCES : to Host Investor Day on October 15th, 2021 in Tampa, FL
GL
2021Nu Skin, Pacira Biosciences fall; Veoneer, Tesla rise
AQ
1  2  3  4  5  6  7Volgende
Volgende evenement op PACIRA BIOSCIENCES, INC.